CREBBP and hematologic disorder: CCS1477 targets the P300/CBP (KAT3A/KAT3B) via interaction with the BD fragment, exhibiting potent antitumor effects in cancer cell lines and animal models.390,391 This has led to its application in monotherapy and in combination with chemotherapeutic drugs in phase I and II clinical trials (NCT04068597, NCT03568656), with the potential to improve therapeutic strategies for both advanced solid tumors and hematological malignancies.